A systematic methodology review of phase i radiation dose escalation trials

Radiotherapy and Oncology

Volumn 95, Issue 2, 2010, Pages 135-141

  Pijls Johannesma, Madelon ^a   Van Mastrigt, Ghislaine ^a   Hahn, Steve M ^c   De Ruysscher, Dirk ^a   Baumert, Brigitta G ^a   Lammering, Guido ^a   Buijsen, Jeroen ^a   Bentzen, Soren M ^b   Lievens, Yolande ^d   Kramar, Andrew ^e   Lambin, Philippe ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF WISCONSIN   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e CENTRE VAL D AURELLE   (France)

Author keywords

Radiotherapy and clinical trial phase I; Systematic review

Indexed keywords

ALGORITHM; BONE METASTASIS; BRAIN CANCER; BREAST CARCINOMA; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL EVALUATION; ESOPHAGUS CARCINOMA; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HEAD AND NECK CARCINOMA; HODGKIN DISEASE; HUMAN; LIVER METASTASIS; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MAXIMUM TOLERATED DOSE; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDLINE; METHODOLOGY; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION SAFETY; RADIOIMMUNOTHERAPY; RECTUM CARCINOMA; REVIEW; SYSTEMATIC REVIEW; UTERINE CERVIX CARCINOMA; ARTICLE; LITERATURE; NEOPLASM; PHASE 1 CLINICAL TRIAL; RADIATION DOSE; TREATMENT OUTCOME;

ALGORITHMS; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; NEOPLASMS; RADIATION DOSAGE; REVIEW LITERATURE AS TOPIC; TREATMENT OUTCOME;

EID: 77956598624     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2010.02.009     Document Type: Review

References (84)

1. EORTC guidelines for phase I trials with single agents in adults. EORTC New Drug Development Committee. Eur J Cancer Clin Oncol 1985;21:1005-7.
2. Bentzen SM, Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 2007;25:4096-103. (Pubitemid 47492954)
3. Belderbos JS, De Jaeger K, Heemsbergen WD, et al. First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol J Eur Soc Ther Radiol Oncol 2003;66:119-26. (Pubitemid 36315821)
4. Blackstock AW, Ho C, Butler J, et al. Phase Ia/Ib chemo-radiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/ B non-small cell lung cancer. J Thorac Oncol 2006;1:434-40. (Pubitemid 47181420)
5. Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005;61:318-28. (Pubitemid 40164423)
6. Byhardt RW, Pajak TF, Emami B, Herskovic A, Doggett RS, Olsen LA. A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: report of Radiation Therapy Oncology Group 84-07. Int J Radiat Oncol Biol Phys 1993;26:459-68. (Pubitemid 23182341)
7. Choi NC, Herndon 2nd JE, Rosenman J, et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionatedaccelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol Official J Am Soc Clin Oncol 1998;16:3528-36. (Pubitemid 28506764)
8. De Ruysscher D, Wanders S, Van Haren E, et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys 2005;62:988-94. (Pubitemid 40884408)
9. Ernst Stecken A, Lambrecht U, Mueller R, Sauer R, Grabenbauer G. Hypofractionated stereotactic radiotherapy for primary and secondary intrapulmonary tumors: first results of a phase I/II study. Strahlentherapie und Onkologie Organ der Deutschen Rontgengesellschaft [et al.] 2006;182:696-702. (Pubitemid 44887170)
10. Garces YI, Okuno SH, Schild SE, et al. Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007;67:995-1001.
11. Hayman JA, Martel MK, Ten Haken RK, et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol Official J Am Soc Clin Oncol 2001;19:127-36. (Pubitemid 32063489)
12. Holloway CL, Robinson D, Murray B, et al. Results of a phase I study to dose escalate using intensity modulated radiotherapy guided by combined PET/CT imaging with induction chemotherapy for patients with non-small cell lung cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol 2004;73: 285-7. (Pubitemid 39601075)
13. Komaki R, Swann RS, Ettinger DS, et al. Phase I study of thoracic radiation dose escalation with concurrent chem, otherapy for patients with limited small-cell lung cancer. Report of Radiation Therapy Oncology Group (RTOG) protocol 97- 12. Int J Radiat Oncol Biol Phys 2005;62:342-50. (Pubitemid 40704448)
14. Le QT, Loo BW, Ho A, et al. Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol 2006;1:802-9. (Pubitemid 47181385)
15. Marks LB, Garst J, Socinski MA, et al. Carboplatin/paclitaxel or carboplatin/ vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium. J Clin Oncol official J Am Soc Clin Oncol 2004;22:4329-40. (Pubitemid 41185153)
16. McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys 2005;63:1010-5. (Pubitemid 41505277)
17. Narayan S, Henning GT, Ten Haken RK, Sullivan MA, Martel MK, Hayman JA, et al. 92.4 or 102.9 Gy on a phase I dose escalation study for non-small cell lung cancer. Lung Cancer Amsterdam, Netherlands 2004;44:79-88. (Pubitemid 38317264)
18. Rosenman JG, Halle JS, Socinski MA, et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 2002;54:348-56. (Pubitemid 35286797)
19. Rosenzweig KE, Mychalczak B, Fuks Z, et al. Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer. Cancer J Sudbury, Mass 2000;6:82-7. (Pubitemid 30469167)
20. Schild SE, McGinnis WL, Graham D, et al. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-smallcell lung cancer. Int J Radiat Oncol Biol Phys 2006;65:1106-11.
21. Socinski MA, Morris DE, Halle JS, et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol Official J Am Soc Clin Oncol 2004;22:4341-50. (Pubitemid 41185154)
22. Socinski MA, Rosenman JG, Halle J, et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. Cancer 2001;92:1213-23.
23. Socinski MA, Rosenman JG, Schell MJ, et al. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I trial. Cancer 2000;89:534-42. (Pubitemid 30640100)
24. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I nonsmall cell lung cancer. Chest 2003;124:1946-55. (Pubitemid 37433596)
25. Wu KL, Jiang GL, Liao Y, et al. Three-dimensional conformal radiation therapy for non-small-cell lung cancer: a phase I/II dose escalation clinical trial. Int J Radiat Oncol Biol Phys 2003;57:1336-44. (Pubitemid 37443974)
26. Yee D, Halperin R, Hanson J, et al. Phase I study of hypofractionated doseescalated thoracic radiotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006;65:466-73.
27. Socinski MA, Marks LB, Garst J, et al. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium. Oncologist 2001;6(Suppl. 1):20-4. (Pubitemid 32155184)
28. Freeman CR, Krischer JP, Sanford RA, et al. Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study. Int J Radiat Oncol Biol Phys 1993;27:197-206. (Pubitemid 23304443)
29. Hudes RS, Corn BW, Werner Wasik M, et al. A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys 1999;43:293-8. (Pubitemid 29091467)
30. Kalapurakal JA, Goldman S, Stellpflug W, et al. Phase I study of intraoperative radiotherapy with photon radiosurgery system in children with recurrent brain tumors: preliminary report of first dose level (10 Gy). Int J Radiat Oncol Biol Phys 2006;65:800-8. (Pubitemid 43795834)
31. Laing RW, Warrington AP, Graham J, Britton J, Hines F, Brada M, et al. Phase I/II study. Radiother Oncol J Eur Soc Ther Radiol Oncol 1993;27:22-9.
32. Werner Wasik M, Scott CB, Nelson DF, et al. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02. Cancer 1996;77:1535-43.
33. Allen AM, Zalupski MM, Robertson JM, et al. Adjuvant therapy in pancreatic cancer: phase I trial of radiation dose escalation with concurrent full-dose gemcitabine. Int J Radiat Oncol Biol Phys 2004;59:1461-7. (Pubitemid 38954069)
34. Brade A, Brierley J, Oza A, et al. Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study. Int J Radiat Oncol Biol Phys 2007;67:1027-36.
35. Koong AC, Le QT, Ho A, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2004;58:1017-21. (Pubitemid 38314781)
36. Morganti AG, Valentini V, Macchia G, et al. 5-fluorouracil-based chemoradiation in unresectable pancreatic carcinoma: phase I-II doseescalation study. Int J Radiat Oncol Biol Phys 2004;59:1454-60. (Pubitemid 38954068)
37. Regine WF, Hanna N, Garofalo MC, et al. Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm. Int J Radiat Oncol Biol Phys 2007;68:172-7. (Pubitemid 46589824)
38. Tsujie M, Nakamori S, Tanaka E, et al. Phase I/II trial of hyperfractionated accelerated chemoradiotherapy for unresectable advanced pancreatic cancer. Jpn J Clin Oncol 2006;36:504-10. (Pubitemid 44592679)
39. Ueno H, Okusaka T, Ikeda M, Tokuuye K. Phase I study of hyperfractionated radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic cancer. Oncology 2004;67:215-21. (Pubitemid 39551704)
40. Forman JD, Duclos M, Shamsa F, Porter AT, Orton C. Hyperfractionated conformal radiotherapy in locally advanced prostate cancer: results of a dose escalation study. Int J Radiat Oncol Biol Phys 1996;34:655-62. (Pubitemid 26069195)
41. Kitamura K, Shirato H, Shinohara N, et al. Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumor-tracking system for prostate cancer: preliminary results of a phase I/II study. Cancer J Sudbury, Mass 2003;9:268-76.
42. Leibel SA, Heimann R, Kutcher GJ, et al. Three-dimensional conformal radiation therapy in locally advanced carcinoma of the prostate: preliminary results of a phase I dose-escalation study. Int J Radiat Oncol Biol Phys 1994;28:55-65. (Pubitemid 24012855)
43. Michalski JM, Purdy JA, Winter K, et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 2000;46:391-402. (Pubitemid 30067789)
44. Ryu JK, Winter K, Michalski JM, et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys 2002;54:1036-46. (Pubitemid 35292614)
45. Zelefsky MJ, Fuks Z, Wolfe T, et al. Locally advanced prostatic cancer: longterm toxicity outcome after three-dimensional conformal radiation therapy - a dose-escalation study. Radiology 1998;209:169-74. (Pubitemid 28464663)
46. Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with threedimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998;41:491-500. (Pubitemid 28275076)
47. Zelefsky MJ, Leibel SA, Kutcher GJ, Kelson S, Ling CC, Fuks Z. The feasibility of dose escalation with three-dimensional conformal radiotherapy in patients with prostatic carcinoma. Cancer J Sci Am 1995;1:142-50.
48. Michalski JM, Winter K, Purdy JA, et al. Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406. Semin Radiat Oncol 2002;12:75-80. (Pubitemid 34246073)
49. Madani I, Duthoy W, Derie C, et al. Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2007;68:126-35. (Pubitemid 46589860)
50. Wu Q, Mohan R, Morris M, Lauve A, Schmidt Ullrich R. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas. I: dosimetric results. Int J Radiat Oncol Biol Phys 2003;56:573-85. (Pubitemid 36546258)
51. Harney J, Goodchild K, Phillips H, Glynne Jones R, Hoskin PJ, Saunders MI. A phase I/II study of CHARTWEL with concurrent chemotherapy in locally advanced, inoperable carcinoma of the oesophagus. Clin Oncol R College Radiol Great Br 2003;15:109-14. (Pubitemid 36527438)
52. Palazzoni G, Nardone L, Cianciulli M, Ciresa M, Ausili Cefaro G. Dose fractionation and biological optimization in breast cancer. Rays 2004;29:333-8.
53. McAfee SL, Powell SN, Colby C, Spitzer TR. Dose-escalated total body irradiation and autologous stem cell transplantation for refractory hematologic malignancy. Int J Radiat Oncol Biol Phys 2002;53:151-6. (Pubitemid 34465819)
54. Dawson LA, Saito NG, Ratanatharathorn V, et al. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease. Int J Radiat Oncol Biol Phys 2004;59:208-18. (Pubitemid 38501526)
55. Scarantino CW, Caplan R, Rotman M, Coughlin C, Demas W, Delrowe J. A phase I/II study to evaluate the effect of fractionated hemibody irradiation in the treatment of osseous metastases - RTOG 88-22. Int J Radiat Oncol Biol Phys 1996;36:37-48. (Pubitemid 26314150)
56. Russell AH, Clyde C, Wasserman TH, Turner SS, Rotman M. Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys 1993;27:117-23. (Pubitemid 23270664)
57. Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 2005;62:1371-8. (Pubitemid 40982057)
58. Freedman GM, Meropol NJ, Sigurdson ER, et al. Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2007;67:1389-93. (Pubitemid 46467159)
59. Movsas B, Hanlon AL, Lanciano R, et al. Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 1998;42:43-50. (Pubitemid 28435594)
60. Calkins AR, Harrison CR, Fowler Jr WC. Hyperfractionated radiation therapy plus chemotherapy in locally advanced cervical cancer: results of two phase I dose-escalation Gynecologic Oncology Group trials. Gynecol Oncol 1999;75:349-55.
61. Epstein BE, Scott CB, Sause WT, et al. Improved survival duration in patients with unresected solitary brain metastasis using accelerated hyperfractionated radiation therapy at total doses of 54.4 gray and greater. Results of Radiation Therapy Oncology Group 85-28. Cancer 1993;71:1362-7. (Pubitemid 23054932)
62. Sause WT, Scott C, Krisch R, et al. Phase I/II trial of accelerated fractionation in brain metastases RTOG 85-28. Int J Radiat Oncol Biol Phys 1993;26:653-7. (Pubitemid 23220165)
63. Lauve A, Morris M, Schmidt Ullrich R, et al. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II - clinical results. Int J Radiat Oncol Biol Phys 2004;60:374-87. (Pubitemid 39233454)
64. Dent SF, Eisenhauer EA. Phase I trial design: are new methodologies being put into practice? Ann Oncol 1996;7:561-6. (Pubitemid 26285634)
65. Hawkins MJ. Early cancer clinical trials: safety, numbers, and consent. J Natl Cancer Inst 1993;85:1618-9. (Pubitemid 23315412)
66. Thall PF, Lee SJ. Practical model-based dose-finding in phase I clinical trials: methods based on toxicity. Int J Gynecol Cancer 2003;13:251-61. (Pubitemid 38222572)
67. Braun TM. Generalizing the TITE-CRM to adapt for early- and late-onset toxicities. Stat Med 2006;25:2071-83. (Pubitemid 43950280)
68. Normolle D, Lawrence T. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method. J Clin Oncol 2006;24:4426-33. (Pubitemid 46630980)
69. Paoletti X, Baron B, Schoffski P, et al. Using the continual reassessment method: lessons learned from an EORTC phase I dose finding study. Eur J Cancer 2006;42:1362-8. (Pubitemid 43922405)
70. Ahn C. An evaluation of phase I cancer clinical trial designs. Stat Med 1998;17:1537-49. (Pubitemid 28367836)
71. Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys 2000;47:1-12. (Pubitemid 30179674)
72. Arbuck SG. Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996. Ann Oncol 1996;7:567-73.
73. Denis F, Garaud P, Bardet E, et al. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 2003;55:93-8. (Pubitemid 36020347)
74. Hoeller U, Tribius S, Kuhlmey A, Grader K, Fehlauer F, Alberti W. Increasing the rate of late toxicity by changing the score? A comparison of RTOG/EORTC and LENT/SOMA scores. Int J Radiat Oncol Biol Phys 2003;55:1013-8. (Pubitemid 36287005)
75. Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 2007;25:5121-7. (Pubitemid 350232293)
76. Lutgens LC, Deutz NE, Gueulette J, et al. Citrulline: a physiologic marker enabling quantitation and monitoring of epithelial radiation-induced small bowel damage. Int J Radiat Oncol Biol Phys 2003;57:1067-74. (Pubitemid 37324125)
77. Barthelemy-Brichant N, Bosquee L, Cataldo D, et al. Increased IL-6 and TGFbeta1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy. Int J Radiat Oncol Biol Phys 2004;58:758-67. (Pubitemid 38221132)
78. Hartsell WF, Scott CB, Dundas GS, et al. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03. Am J Clin Oncol 2007;30:368-76. (Pubitemid 47356681)
79. Heemsbergen WD, Peeters ST, Koper PC, Hoogeman MS, Lebesque JV. Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. Int J Radiat Oncol Biol Phys 2006;66:3-10. (Pubitemid 44175664)
80. Tucker SL, Dong L, Cheung R, et al. Comparison of rectal dose-wall histogram versus dose-volume histogram for modeling the incidence of late rectal bleeding after radiotherapy. Int J Radiat Oncol Biol Phys 2004;60: 1589-601. (Pubitemid 39601877)
81. Husing J, Sauerwein W, Hideghety K, Jockel KH. A scheme for a dose-escalation study when the event is lagged. Stat Med 2001;20:3323-34. (Pubitemid 33100644)
82. Belderbos JS, Heemsbergen WD, De Jaeger K, Baas P, Lebesque JV. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using threedimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:126-34. (Pubitemid 44175671)
83. Rosenzweig KE, Fox JL, Yorke E, et al. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer 2005;103:2118-27. (Pubitemid 40605120)
84. Leibel SA, Zelefsky MJ, Kutcher GJ, Burman CM, Kelson S, Fuks Z. Threedimensional conformal radiation therapy in localized carcinoma of the prostate: interim report of a phase 1 dose-escalation study. J Urol 1994;152:1792-8. (Pubitemid 24322631)